RxDoctor Payments Data

Paula Bergamini, MD

Internal Medicine · Arlington, VANPI 1225099112

Payments from drug & device makers

$1,406in general payments, 2019–2025

Across 60 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$164
  • Boehringer Ingelheim$159
  • AstraZeneca$143
  • Novo Nordisk$112
  • AbbVie$107
  • Amgen$102
  • plus $619 from 21 others

What the payments were for

  • Food & beverage$1,406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,406 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$170,962
Medicare patients
413
Services billed
1,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$67,923
OzempicSemaglutide38$45,224
MounjaroTirzepatide26$40,426
TrulicityDulaglutide21$33,982
JardianceEmpagliflozin32$33,532
FarxigaDapagliflozin Propanediol20$16,478
LinzessLinaclotide13$12,983
Estradiol37$5,680
Rosuvastatin Calcium280$4,919
Atorvastatin Calcium394$3,869
Bupropion XlBupropion Hcl98$3,706
Levothyroxine Sodium297$3,543
Tolterodine Tartrate ErTolterodine Tartrate17$3,372
SynthroidLevothyroxine Sodium91$3,333
Duloxetine Hcl101$2,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$44$74,40847 claims
PfizerEliquis, Paxlovid$95$69,35290 claims
Novo NordiskOzempic$112$45,22438 claims
Boehringer IngelheimJardiance$159$33,53232 claims
AstraZenecaFarxiga$143$16,47820 claims
AbbVieLinzess, Synthroid$107$16,316104 claims
Almatica Pharma LLCSertraline Hcl$28$92180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →